This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatment
Study Type
OBSERVATIONAL
Enrollment
200
Participants will receive ATG/ALG according to standard dosing protocols as per clinical guidelines. During treatment, we will monitor and document any adverse reactions, including their type, severity, duration, and any necessary interventions or changes in treatment plan.
Regenerative Medicine Center and Red Blood Cell Disorders Center
Tianjin, China
RECRUITINGPercentage of patients with serum sickness and its severity
Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess its severity
Time frame: Within 4 weeks after ATG/ALG infusion
Percentage of patients with liver and kidney function damage and its severity
Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess its severity
Time frame: During ATG/ALG infusion (typically from d1 to d6) and within 4 weeks after ATG/ALG infusion
Percentage of patients with infusion reaction and its severity
Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess its severity
Time frame: During ATG/ALG infusion(typically from d1 to d6)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.